Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet

被引：15

作者：

Hubacek, Petr ^{[1
]}

Keslova, Petra ^{[1
]}

Formankova, Renata ^{[1
]}

Pochop, Pavel ^{[2
]}

Cinek, Ondrej ^{[3
]}

Zajac, Miroslav ^{[4
]}

Lochmanova, Jana ^{[5
,6
]}

Stary, Jan ^{[1
]}

Sedlacek, Petr ^{[1
]}

机构：

[1] Charles Univ Prague, Dept Paediat Haematol & Oncol, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic

[2] Charles Univ Prague, Dept Ophthalmol Children & Adults, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic

[3] Charles Univ Prague, Dept Paediat, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic

[4] Charles Univ Prague, Dept Microbiol, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic

[5] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Dept Internal Med, Brno, Czech Republic

[6] Masaryk Univ, Brno, Czech Republic

来源：

PEDIATRIC TRANSPLANTATION | 2009年 / 13卷 / 07期

关键词：

cytomegalovirus; transplantation; ganciclovir resistance; cidofovir; foscarnet; PHARMACOKINETIC PROPERTIES; IMMUNOCOMPROMISED PATIENTS; ANTIVIRAL ACTIVITY; THERAPEUTIC USE; GANCICLOVIR; INFECTION;

D O I：

10.1111/j.1399-3046.2008.01070.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

We report an 18-yr-old female patient with repeated CMV reactivations after HSCT treated by several pre-emptive courses of virostatic therapy. Seven months after HSCT, she developed CMV encephalitis/retinitis. Initial therapy with GCV and hyperimmune globulin failed, and later on GCV-resistant strain was detected. Continual increase of CMV DNA in peripheral blood led us to combined therapy with CDV and FCV, which was successful and free of severe renal toxicity. To our best knowlegde, this is the first reported case of successful CMV treatment with a combination of CDV and FCV.

引用

页码：919 / 922

页数：4

共 7 条

[1] Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis [J].

Battiwalla, Minoo ;

Wu, Yiyuan ;

Bajwa, Rajinder P. S. ;

Radovic, Marija ;

Almyroudis, Nikolaos G. ;

Segal, Brahm H. ;

Wallace, Paul K. ;

Nakamura, Ryotaro ;

Padmanabhan, Swaminathan ;

Hahn, Theresa ;

McCarthy, Philip L., Jr. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (07) :765-770

[2] Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation [J].

Cesaro, S ;

Zhou, X ;

Manzardo, C ;

Buonfrate, D ;

Cusinato, R ;

Tridello, G ;

Mengoli, C ;

Palù, G ;

Messina, C .

JOURNAL OF CLINICAL VIROLOGY, 2005, 34 (02) :129-132

[3] ANALYSIS OF THE UL97 PHOSPHOTRANSFERASE CODING SEQUENCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES AND IDENTIFICATION OF MUTATIONS CONFERRING GANCICLOVIR RESISTANCE [J].

CHOU, SW ;

ERICE, A ;

JORDAN, MC ;

VERCELLOTTI, GM ;

MICHELS, KR ;

TALARICO, CL ;

STANAT, SC ;

BIRON, KK .

JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :576-583

[4] FOSCARNET - A REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN IMMUNOCOMPROMISED PATIENTS WITH CYTOMEGALOVIRUS RETINITIS [J].

CHRISP, P ;

CLISSOLD, SP .

DRUGS, 1991, 41 (01) :104-129

[5] Ganciclovir - An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients [J].

McGavin, JK ;

Goa, KL .

DRUGS, 2001, 61 (08) :1153-1183

[6] Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation [J].

Narimatsu, H. ;

Kami, M. ;

Kato, D. ;

Matsumura, T. ;

Murashige, N. ;

Kusumi, E. ;

Yuji, K. ;

Hori, A. ;

Shibata, T. ;

Masuoka, K. ;

Wake, A. ;

Miyakoshi, S. ;

Morinaga, S. ;

Taniguchi, S. .

TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (01) :11-15

[7] FOSCARNET - A REAPPRAISAL OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN IMMUNOCOMPROMISED PATIENTS WITH VIRAL-INFECTIONS [J].

WAGSTAFF, AJ ;

BRYSON, HM .

DRUGS, 1994, 48 (02) :199-226

← 1 →